This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Webb, P. M. Articles by Spurdle, A. B. Search for Related Content PubMed PubMed Citation Articles by Webb, P. M. Articles by Spurdle, A. B.

Double-Strand Break Repair Gene Polymorphisms and Risk of Breast or Ovarian Cancer

¹ Population and Clinical Sciences Division and ² Cancer and Cell Biology Division, Queensland Institute of Medical Research and University of Queensland; ³ School of Public Health, Queensland University of Technology, Brisbane, Queensland, Australia; ⁴ Centre for Genetic Epidemiology, University of Melbourne; and ⁵ Cancer Epidemiology Centre, Council of Victoria, Carlton, Victoria, Australia

Requests for reprints: Amanda B. Spurdle, Cancer and Cell Biology Division, Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia. Phone: 61-7-3362-0371; Fax: 61-7-3362-0105. E-mail: mandyS{at}qimr.edu.au

Deficiencies in DNA repair have been hypothesized to increase cancer risk and excess cancer incidence is a feature of inherited diseases caused by defects in DNA damage recognition and repair. We investigated, using a case-control design, whether the double-strand break repair gene polymorphisms RAD51 5' untranslated region –135 G > C, XRCC2 R188H G > A, and XRCC3 T241M C > T were associated with risk of breast or ovarian cancer in Australian women. Sample sets included 1,456 breast cancer cases and 793 age-matched controls ages under 60 years of age, 549 incident ovarian cancer cases, and 335 controls of similar age distribution. For the total sample and the subsample of Caucasian women, there were no significant differences in genotype distribution between breast cancer cases and controls or between ovarian cancer cases and combined control groups. The crude odds ratios (OR) and 95% confidence intervals (95% CI) associated with the RAD51 GC/CC genotype frequency was OR, 1.10; 95% CI, 0.80-1.41 for breast cancer and OR, 1.22; 95% CI, 0.92-1.62 for ovarian cancer. Similarly, there were no increased risks associated with the XRCC2 GA/AA genotype (OR, 0.98; 95% CI, 0.76-1.26 for breast cancer and OR, 0.93; 95% CI, 0.69-1.25 for ovarian cancer) or the XRCC3 CT/TT genotype (OR, 0.92; 95% CI, 0.77-1.10 for breast cancer and OR, 0.87; 95% CI, 0.71-1.08 for ovarian cancer). Results were little changed after adjustment for age and other measured risk factors. Although there was little statistical power to detect modest increases in risk for the homozygote variant genotypes, particularly for the rare RAD51 and XRCC2 variants, the data suggest that none of these variants play a major role in the etiology of breast or ovarian cancer.

This article has been cited by other articles:

				J. Brooks, R. E. Shore, A. Zeleniuch-Jacquotte, D. Currie, Y. Afanasyeva, K. L. Koenig, A. A. Arslan, P. Toniolo, and I. Wirgin Polymorphisms in RAD51, XRCC2, and XRCC3 Are Not Related to Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 1016 - 1019. [Full Text] [PDF]

				J. Beesley, S. J. Jordan, A. B. Spurdle, H. Song, S. J. Ramus, S. K. Kjaer, E. Hogdall, R. A. DiCioccio, V. McGuire, A. S. Whittemore, et al. Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2557 - 2565. [Abstract] [Full Text] [PDF]

				P. Bhatti, D. M. Church, J. L. Rutter, J. P. Struewing, and A. J. Sigurdson Candidate Single Nucleotide Polymorphism Selection using Publicly Available Tools: A Guide for Epidemiologists Am. J. Epidemiol., October 15, 2006; 164(8): 794 - 804. [Abstract] [Full Text] [PDF]

				The Breast Cancer Association Consortium Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst, October 4, 2006; 98(19): 1382 - 1396. [Abstract] [Full Text] [PDF]